Abstracts tagged "certolizumab pegol and spondylarthritis"

Abstract Number: 1799 • 2013 ACR/ARHP Annual Meeting
Effect Of Certolizumab Pegol Over 48 Weeks In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Robert B. M. Landewé¹, Martin Rudwaleit², Désirée M. van der Heijde³, Maxime Dougados⁴, Philip Mease⁵, John D. Reveille⁶, Jessica Walsh⁷, Alan J. Kivitz⁸, Walter P. Maksymowych⁹, Jürgen Braun¹⁰, Atul A. Deodhar¹¹, Christian Stach¹², Bengt Hoepken¹², Pritibha Singh¹² and Joachim Sieper¹³, ¹Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ²Endokrinologikum Berlin, Berlin, Germany, ³Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁵Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁶Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁷Rheumatology, University of Utah Hospital, Salt Lake City, UT, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹Medicine, University of Alberta, Edmonton, AB, Canada, ¹⁰Rheumazentrum Ruhrgebiet, Herne, Germany, ¹¹Div of Arthritis & Rheum OP-09, Oregon Health & Science University, Portland, OR, ¹²UCB Pharma, Monheim, Germany, ¹³Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: Previous reports of RAPID-axSpA have demonstrated the efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in patients (pts) with axial spondyloarthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].